Cancer Cachexia Clinical Trial
Official title:
Relationship Between TNF Alpha Gene Polymorphisms and the Pathogenesis of Cachexia in Cancer Patients Treated With Chemotherapy
Cachexia not only directly increases the morbidity and mortality, it also aggravates the side
effects of chemotherapy and reduces the overall quality of life that is often considered the
major and direct cause of morbidity of a large proportion (>40%) of cancer patients.
Individuals with upper gastrointestinal tumors have the highest rate of developing cachexia
associated complications. Chemical and physical signals render an environment conducive for
disuse and untenable for proper muscle function leading to wasting.
Till now, several functional single-nucleotide polymorphisms (SNPs) within TNF-α gene have
been identified and described as cancer related genetic alterations.
Cachexia is a devastating syndrome that is observed in the majority of end stage cancer
patients. Primary symptoms of cancer cachexia comprise of progressive loss in weight and
exhaustion of host skeletal muscle tissue as well as adipose tissue reserves.
Cancer cachexia is defined as a multifactorial syndrome, characterized by anorexia as well as
diminished body weight, loss of skeletal muscle, and atrophy of adipose tissue (Fearon et
al., 2011). Specifically, weight loss of more than 5% over 6 months span in previously
healthy individuals or more than 2% in subjects with depletion of current body weight (BMI
less than 20 kg/m2) or in individuals with reduced appendicular muscle index (males less than
7.26 kg/m2 and females less than 5.45 kg/m2) constitute the diagnosis of cancer cachexia.
Among potential mechanisms involved in the development of cachexia, the primary initial
process is probably the systemic inflammatory response followed by increased production of
pro-inflammatory cytokines, such as TNF-α. Multiple biological activities of TNF-α were found
in numerous physiological states, including the regulation of cell differentiation,
proliferation, apoptosis and metabolism .
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02553187 -
A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia
|
Phase 4 | |
Recruiting |
NCT02848807 -
Chemotherapy-related Toxicity, Nutritional Status and Quality of Life
|
N/A | |
Active, not recruiting |
NCT01206335 -
Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia
|
Phase 2 | |
Completed |
NCT00378131 -
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia
|
Phase 2 | |
Completed |
NCT02359123 -
Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients
|
N/A | |
Completed |
NCT00267358 -
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.
|
Phase 2 | |
Completed |
NCT03144128 -
Vitamin D for Muscle Metabolic Function in Cancer Cachexia
|
N/A | |
Completed |
NCT01614990 -
Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
|
Phase 2 | |
Recruiting |
NCT04067167 -
Flexi Band Resistance Training Versus EMS Exercise in Patients With the Diagnosis of Malignant Diseases
|
N/A | |
Recruiting |
NCT04065815 -
Protein-rich Nutritional Therapy Combined With Time-efficient Exercise in Cancer Therapy
|
N/A | |
Active, not recruiting |
NCT03851133 -
Florida Pancreas Collaborative Next Generation Biobank
|
||
Completed |
NCT05264038 -
A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514
|
Phase 1 | |
Recruiting |
NCT04127981 -
Medical Imaging of Cachexia
|
N/A | |
Not yet recruiting |
NCT05262192 -
Nutrition Education and Quality of Life in Cancer Cachexia
|
N/A | |
Completed |
NCT04153019 -
PSYCHO-EDUCATIONAL AND REHABILITATIVE INTERVENTION FOR CANCER CACHEXIA (PRICC)
|
N/A | |
Terminated |
NCT02066363 -
Study of Parenteral Nutrition to Patients With Gastrointestinal Cancer
|
N/A | |
Terminated |
NCT01505764 -
The Role of Ghrelin in Cancer Cachexia
|
Phase 2 | |
Completed |
NCT00219817 -
Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
|
Phase 2 | |
Completed |
NCT00094562 -
A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss
|
Phase 2 | |
Recruiting |
NCT05915325 -
Physical Training for Elderly Cancer Patients With Cachexia
|
N/A |